Germany · Delayed Price · Currency is EUR NovaBridge Biosciences Statistics
Total Valuation
FRA:0VY has a market cap or net worth of EUR 166.30 million. The enterprise value is -15.88 million.
| Market Cap | 166.30M |
| Enterprise Value | -15.88M |
Important Dates
The next estimated earnings date is Friday, August 21, 2026.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +17.96% |
| Shares Change (QoQ) | +10.88% |
| Owned by Insiders (%) | 7.29% |
| Owned by Institutions (%) | 20.31% |
| Float | 64.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.09, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.09 |
| Quick Ratio | 7.91 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.15 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.89% and return on invested capital (ROIC) is -330.29%.
| Return on Equity (ROE) | -40.89% |
| Return on Assets (ROA) | -24.90% |
| Return on Invested Capital (ROIC) | -330.29% |
| Return on Capital Employed (ROCE) | -40.35% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -2.51M |
| Employee Count | 30 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.00% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -31.00% |
| 50-Day Moving Average | 1.65 |
| 200-Day Moving Average | 2.81 |
| Relative Strength Index (RSI) | 44.09 |
| Average Volume (20 Days) | 100 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.81 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -80.29M |
| Pretax Income | -75.24M |
| Net Income | -75.24M |
| EBITDA | -80.23M |
| EBIT | -80.29M |
| Earnings Per Share (EPS) | -0.79 |
Balance Sheet
The company has 179.57 million in cash and 2.61 million in debt, with a net cash position of 176.96 million.
| Cash & Cash Equivalents | 179.57M |
| Total Debt | 2.61M |
| Net Cash | 176.96M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 196.69M |
| Book Value Per Share | 1.70 |
| Working Capital | 162.36M |
Cash Flow
In the last 12 months, operating cash flow was -17.54 million and capital expenditures -5,962, giving a free cash flow of -17.55 million.
| Operating Cash Flow | -17.54M |
| Capital Expenditures | -5,962 |
| Depreciation & Amortization | 59,690 |
| Net Borrowing | n/a |
| Free Cash Flow | -17.55M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:0VY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.96% |
| Shareholder Yield | -17.96% |
| Earnings Yield | -45.24% |
| FCF Yield | -10.55% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |